Targeting MDM2
to Regenerate Bone
to Regenerate Bone
First-in-Class PROTAC Therapy for Bone Regeneration
A Team Built
to Redefine Bone Therapeutics
to Redefine Bone Therapeutics
From molecular design to clinical translation
SCROLL
/
Why Current Bone Therapies
Leave Patients Behind
For patients facing bone defects — from dental implants to spinal fusion — current treatments fall short. Inflammatory complications, prohibitive costs, and poor outcomes in high-risk patients represent a significant unmet clinical need.
Inhibition is temporary. Degradation is definitive.
The Mechanistic Ceiling of
Conventional Inhibition
Conventional inhibitors work by occupying target proteins — but they cannot clear the accumulated regulators that actively block bone growth. True regeneration requires more than blocking a signal. It requires removing the fundamental brake.
Accumulation of negative regulators is the critical barrier.
The New Paradigm in
Bone Therapeutics
DentX Biomed pioneers the world's first PROTAC therapy engineered for bone regeneration. By selectively degrading MDM2, we unlock the body's intrinsic ability to heal — with small molecule precision, biologic-level efficacy, and a fraction of the cost.
Highly selective MDM2 degradation via PROTAC
Chemical synthesis: scalable, affordable, stable
Expandable platform across dental, spine, and osteoporosis
Chemical synthesis: scalable, affordable, stable
Expandable platform across dental, spine, and osteoporosis
Let's Build the Future of Bone Regeneration Together.
We are seeking strategic investors, global partners, and clinical collaborators.
Contact us to explore opportunities.
Contact us to explore opportunities.
